A family with an unusual myotonic and myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): a challenge for future molecular studies by G. Meola et al.
Pergamon 
Neuromusc. Disord, Vol. 6. No. 3, pp. 143-150, 1996 
Copyright © 1996 Elsevier Science Ltd. All rights reserved 
Printed in Great Britain 
0960-8966/96 $15.00 + .00 
0960-8966(95) 00040-2 
A FAMILY WITH AN UNUSUAL MYOTONIC AND MYOPATHIC 
PHENOTYPE AND NO CTG EXPANSION (PROXIMAL MYOTONIC 
MYOPATHY SYNDROME): A CHALLENGE FOR FUTURE 
MOLECULAR STUDIES 
GIOVANNI MEOLA*t, VALERIA SANSONE*, STEFANIA RADICE*, SHANA SKRADSKI+ 
and LOUIS PTACEK + 
*Department of Neurology, Division of Neurology I, University of Milan, San Donato Hospital, V. Morandi, 
30-20097, San Donato Milanese, Milan, Italy; + Department of Human Genetics, University of UTAH Health Sciences 
Center, Salt Lake City, UT 84132, U.S.A. 
(Received 14 August 1995; revised 10 October 1995; accepted 19 October 1995) 
Abstraet--Myotonic dystrophy (DM) is a well-defined autosomal dominant disorder charac- 
terized by myotonia, muscle weakness, cardiac onduction defects, cataracts, and endocrine 
abnormalities. Recently a newly recognized isorder, similar to but distinct from DM, has 
been observed with multisystem findings including intermittent myotonia, proximal myopathy, 
and occasional cardiac conduction disturbances. This disorder has been called proximal 
myotonic myopathy (PROMM). No history of anticipation is present and there is no linkage 
to the gene locus for DM or to the loci for the muscle sodium or chloride channels. This 
report describes a family with a normal size of the CTG trinucleotide repeat expansion of the 
DM gene in which affected individuals have myotonia (intermittent, exacerbated by cold), 
bilateral cataracts, mild hypogonadism and mild temporal atrophy. Affected individuals also 
have proximal muscle weakness, facial involvement, nonspecific abnormalities on muscle 
biopsy, normal cardiac onduction, and no glucose intolerance. The absence of trinucleotide 
repeat expansion i  the DM gene is consistent with this family being affected by a disorder 
distinct from DM, possibly a form of PROMM. Copyright © 1996 Elsevier Science Ltd. 
Key words: Myotonic dystrophy, trinucleotide expansion, amplification, ion channel disorders, 
myotonia. 
INTRODUCTION 
Myotonic dystrophy (DM) is a multisystem, 
autosomal, dominant disorder caused by an 
abnormal, unstable xpansion of a trinucleotide 
CTG repeat on chromosome 19 in a gene that 
encodes a protein kinase [1-7]. Almost all 
patients (98-100%) with classical clinical 
features of DM (myotonia, cognitive impair- 
ment, distal weakness, endocrine and cardiac 
conduction abnormalities) [1--4] have the 
abnormal CTG repeat expansion. An inverse 
relationship exists between age at onset and size 
of the repeat, providing a genetic explanation 
for the appearance of more severe manifesta- 
tions occurring at an earlier onset in successive 
generations, e.g. anticipation [8, 9]. Although 
tAuthor to whom correspondence should be addressed. 
the underlying molecular mechanisms of DM 
and the exact cause for the great variability in 
clinical presentation are still unknown, the size 
of the CTG repeat expansion in leucocyte 
DNA appears to correlate reasonably well with 
the age of onset and the severity of skeletal and 
cardiac muscle disease [3, 10-131. However 
there are some families with affected individu- 
als who have certain phenotypic similarities to 
DM in whom there is no abnormal CTG repeat 
expansion of the DM gene [4]. 
Recently a myotonic myopathy has been 
described in which affected individuals have a 
normal CTG expansion of the DM gene associ- 
ated with a particular phenotype, characterized 
by myotonia, proximal weakness and cataracts 
[14]. These patients have only some of the usual 
features of DM [7, 15, 16]. The underlying 
genetic defect in this newly described isorder is 
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still unknown. This syndrome has been called 
proximal myotonic myopathy (PROMM) and 
is now recognized as a new clinical disorder 
that is similar to but distinct from DM [14, 16]. 
In this report we highlight the clinical and 
genetic features in our family and have 
compared our findings to those seen in both 
DM and PROMM. 
We evaluated four patients from one family 
and obtained historical information about five 
members spanning five generations. The 
affected individuals have a dominantly inher- 
ited disorder which has similarities to DM but 
differs in several essential features: (i) there is 
no anticipation throughout five generations; (ii) 
there are only mild myotonic symptoms in a 
few patients, and this varies in severity, 
decreasing as the outside temperature increases; 
(iii) weakness is mainly proximal and is vari- 
ably present; (iv) muscle histopathology is mild 
and nonspecific; (v) there are no cardiac 
conduction abnormalities; and (vi) the size of 
the trinucleotide CTG expansion on the DM 
gene is normal. 
Our findings suggest that PROMM may 
include patients with different clinical features, 
similar to, but distinct from DM or benign 
myotonic disorders, and that as more PROMM 
families are evaluated, it is possible that more 
extensive clinical and genetic heterogeneity will 
be identified. 
PATIENTS AND METHODS 
Clinical investigations were performed in four 
patients (mean age 47.6 yr, range 32-71 yr) and 
genetic linkage analysis was carried out in all 
known affected members (see pedigree, Fig. 1). 
No information was available for patients from 
the first generation. Patient 11-2 died at 60 yr of 
age from a heart attack and had bilateral 
cataracts. Patient 11-5 was wheelchair confined 
when she died, had diabetes and cataracts. 
Patient III-1 also had bilateral cataracts and 
hypogonadism while patient III-4 was known 
to have bilateral cataracts and diabetes. Patient 
111-9 works as a farmer and complains of no 
weakness at all; he had slightly elevated fasting 
glucose levels and mild glucose intolerance. 
Patient III-11 is healthy and has never 
consulted a physician other than for the pres- 
ence of multiple lipomas over his arms. Patient 
IV-4 is a physical education instructor at a 
competitive l vel and only has mild bilateral 
cataracts. Patients from the fifth generation are 
in good health. Details about patients 111-13 
and IV-2, IV-6 and IV-7 are listed in Tables 1 
and 2 and Fig. 2. Clinical examination was 
performed by one of the authors (GM). Age at 
onset was recorded as the age when symptoms 
were first recalled (such as distal weakness, 
myotonia, cardiac conduction abnormalities, 
the presence of cataracts and the presence of 




O- I  
12 13 15 
• Affected by history (cataract, hyperglycemia, myalgias with mild distal/proximal weakness) 
O Affected by history 
Fig. 1. Family pedigree. 
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Muscle strength was evaluated according to a 
five-point disability scale (MRC) in which the 
highest score signifies no muscle impairment. 
The MDRS scale [17] for DM patients was not 
adopted to classify our patients because proxi- 
mal involvement is considered in this scale as a 
progression of severity of disease following 
distal involvement. 
Needle EMG was performed in all patients. 
Percussion myotonia (thenar muscle) and grip 
myotonia, taking into account he times taken 
to bring the fingers from a flexed to an 
extended position in 1 min, were also evaluated 
(Table 2). 
After obtaining informed consent, a muscle 
biopsy was obtained from the right biceps 
muscle under local anaesthesia n all patients. 
Cryostat sections 10 /2m thick were processed 
and histological and histochemical reactions 
was performed as previously described [18]. 
Gonadal function was assessed by analysis of 
FSH, LH, LIH, GnRH, and thyroid function by 
T3, T4, and TSH levels. Glucose metabolism was 
studied by measurement of fasting glucose level, 
response to oral glucose tolerance testing and by 
determination f islet cell antibodies [19]. 
Cardiac evaluation included standard ECG 
recording, Holter ECG, echocardiography and 
cardiac MRI [20]. 
Brain MRI was performed in all patients to 
identify any possible white or grey matter 
involvement as previously described in DM 
patients [21]. 
DNA was extracted from peripheral blood 
leukocytes and skeletal muscle from all patients 
to determine the size of CTG repeat by 
Fig. 2. (a) Facial appearance with mild temporal atrophy of the four patients examined; (b) III-13 slight atrophy with 
proximal weakness; (c) IV-2 no muscle weakness except a proximal atrophy with scapular winging and calf hypertrophy; 
(d) IV-6 proximal weakness; (e) IV-7 no muscle weakness except a slight proximal atrophy and calf 
hypertrophy. 
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Table 1. Clinical and genetic data of four PROMM patients 
Patient II I- 13 IV-2 IV-6 IV-7 
Age (yr) 





Gonadal  function 
Gamma-GT 
Fast ing glycemia 









EF  50% Mild LVH 
Mild aortic insuff. 
43 37 32 
23 16 25 
Maternal Paternal Paternal 
Lens opacity + Lens opacity 
Mild hypogonadism Mild hypogonadism 
- - Accelerated A-V conduction 
- - Mitral prolapse 
Cardiac MRI  - - - 
Brain MRI  Multiple ischemic lesions - - - 
(CTG)  n repeats 5/12 12/21 5/20 10/13 
EF: ejection fraction; LVH: left ventricular hypertrophy; normal data -; presence +. The number of CTG repeats is indicated for both 
alleles. Detailed information concerning different symptoms and tests is given in the Patients and Methods section. 
Table 2. Neuromuscular involvement 
Patient I11-13 IV-2 IV-6 IV-7 
Cal f  hypertrophy - + + 
Distal atrophy + - - 
Proximal atrophy + ++ + + 
Distal weakness 4-5 bilat 5 bilat 3-4 bilat 5 bilat 
Proximal weakness 3 bilat 5 bilat 2-3 bilat 4-5 bilat 
Deep tendon reflexes Normal  Normal  Normal  Normal  
Temperature-sens. myotonia - + + - 
Grip myotonia R 87 87 18 90 
L 85 86 16 86 
CK  levels (U/L) <195 321 <195 <195 
EMG myopathic signs - - 
myotonic signs + + + + 
Ring-binden fibres - - - 
Sarcoplasmic masses . . . .  
Central nuclei + + ++ + 
Necrotic fibres - - - 
Absence of clinical signs -; presence of clinical signs +; degree of weakness is expressed according to MRC*.  See text for clinical and 
methodological details, mildly present = +; moderately present = ++. 
* Medical Research Council. Aids to the Examinat ion of the Peripheral Nervous System. Memorandum 45, Pendragon House, London, 
1976. 
Southern blot and PCR reactions [22]. The 
DNA samples were digested with ECORI and 
electrophoresed on an 0.8% or 1% agarose gel. 
The DNA was transferred from the gel to a 
nylon membrane and hybridized with the 32p_ 
pMDY1 probe, a 1.4 kb Bam H1 fragment 
containing the unstable repeat region. The 
membrane was washed and analysed by autora- 
diography. PCR was performed using the 
genomic DNA samples as templates and a pair 
of oligonucleotide primers closely flanking the 
triplet region. The PCR products were analysed 
using 6% polyacrylamide gel electrophoresis 
followed by autoradiography [22]. Genetic 
linkage analysis was performed to test the 
hypothesis that the disease allele is linked to the 
myotonic dystrophy locus (Marker Mfd5). A 
marker tightly linked to the chromosome 17 
voltage-gated sodium channel locus (HGH2) 
known to cause two other myotonic disorders, 
hyperkaliemic periodic paralysis and paramy- 
otonia congenita [23-26] was analysed. Primers 
were end-labelled, used in PCR reactions, and 
electrophoresed using standard protocols [27]. 
Gels were transferred to filter paper and 
exposed to X-ray film for 1--4 days at -80°C. 
Genotypes were analysed using maximum like- 
lihood methods to perform pairwise linkage 
analysis with MLINK program of the 
LINKAGE system [28]. Two-point analysis of 
each marker was performed using an autoso- 
mal dominant model, a penetrance of 0.95, and 
gene frequencies of 0.001 for the disease allele 
and 0.999 for the normal allele. Analysis was 
also performed with assumed penetrance 
ranging from 0.7 to 0.99. 
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RESULTS 
Three of the four affected individuals that we 
have examined originally appeared to have a 
very mild form of DM. Most of the family 
members have undergone linkage analysis but 
have never had a physical examination because 
they have had no complaints. The onset of 
symptoms in symptomatic individuals falls 
between 16 and 27 yr of age and the disease is 
passed through both paternal and maternal 
transmission. Of the four patients examined, 
two showed no muscular impairment. None of 
these affected members complained of muscle 
weakness or recalled a prior history of weak- 
ness. Most patients are farmers and are able to 
perform strenuous exercise and manual abour. 
In particular patient IV-4 is a physical educa- 
tion trainer at a competitive l vel. Patient III- 
13 (Fig. 2b) has mainly proximal weakness with 
normal deep tendon reflexes. Patient IV-6 (Fig. 
2d) only has more proximal weakness; patient 
IV-2 (Fig. 2c) has no weakness with proximal 
atrophy, scapular winging and calf hypertro- 
phy. Patient IV-7 (Fig. 2e) has mild proximal 
weakness with slight proximal atrophy and calf 
hypertrophy. One (IV-6) of the four affected 
patients has prominent grip myotonia, which 
clearly improves with repeated muscle contrac- 
tions (warm-up) (see Table 2). All four patients 
examined with mild temporal atrophy (Fig. 2a) 
have lens opacities and two of the four have 
mild hypogonadism. 
Cardiac conduction is normal in the four 
affected individuals examined and no history of 
cardiac arrhythmias is present in the affected 
family members not examined. There are 
nonspecific alterations on echocardiography in 
the 71-yr-old patient and patient IV-7 has 
mitral valve prolapse. Cardiac MRI showed no 
structural abnormality. 
Brain MRI was normal in all patients except 
for the 71-yr-old patient who had multiple 
nonspecific ischaemic lesions. 
CK levels were normal in all members diag- 
nosed as affected based upon their history and 
in three out of the four patients examined. The 
CK values showed no correlation with the pres- 
ence of proximal or distal weakness. 
EMG studies revealed myotonic discharges in 
all the muscles ampled in all four patients who 
were investigated. 
Muscle biopsy analysis showed a mild to 
moderate increase in central nuclei. There were 
no ring-binden, sarcoplasmic masses, or 
necrotic fibres. 
Leucocyte and skeletal muscle DNA testing 
showed normal size for the CTG repeat of the 
DM gene in all affected individuals studied. 
Linkage analysis between this kindred and 
markers tightly linked to the myotonic dystro- 
phy and iperkaliemic periodic paralysis loci 
(Mfd5 and HGH2) demonstrated obligate 
recombinational events. Lod scores were less 
than for recombination values of 0-0.05. 
Because of the small size of the pedigree, it is 
not possible to exclude a large region flanking 
the markers with high statistical significance. 
However, these results suggest hat the disease 
locus in this family is distinct from the 
myotonic dystrophy locus and the chromosome 
17 sodium channel gene. 
DISCUSSION 
The clinical diagnosis of DM has previously 
been based upon a distinct pattern of distal 
muscle wasting, myotonia and multi-organ 
involvement in familes having a clear autoso- 
mal dominant ransmission [7, 15]. An expan- 
sion of 50-2000 CTG repeats in the 3' 
untranslated region of a putative protein kinase 
gene on chromosome 19 occurs in 98-100% of 
patients [4] and seems to define true cases of 
DM. Anticipation (i.e. increasing clinical sever- 
ity with earlier age at onset throughout differ- 
ent generations) is inversely correlated with size 
of repeat and is considered one of the typical 
features of DM [8, 9]. 
CTG expansion varies between different 
tissues and only recently have some authors 
correlated repeat size to severity of skeletal and 
cardiac involvement [12, 13]. There is in general 
a reasonable correlation between CTG repeat 
size measured in leucocyte DNAand the 
phenotypic manifestations in DM patients [22, 
29]. However, Thornton et al. [4] have 
described three patients with several clinical 
features compatible with myotonic dystrophy 
(myotonia, lens opacities, cardiac conduction 
defects, endocrine abnormalities, and muscle 
histopathology compatible with DM) and 
several totally atypical features. The affected 
individuals had weakness that was mainly 
proximal, instead of the typical distal wasting 
in DM. Their limb muscles were large or hyper- 
trophied. No CTG repeat expansion was found 
in leucocyte or muscle DNA and there was no 
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Table 3a. Clinical and genetic heterogeneity in DM 
Features of DM Atypical DM without PROMM Our family 
CTG expansion 
Autosomal dominant pattern Yes Yes Yes 
Anticipation No No No 
Age at onset (yr) 30~4 20--40 32-71 
Baldness Yes No No 
Cataracts Yes Yes Yes 
Long lean face No No No 
Small sternocl, muscles Yes No No 
Myotonic symptoms Yes Yes Mild, temperature-sensitive 
Grasp myotonia Yes Yes Intermittent 
Percussion myotonia Yes Intermittent, asymmetrical Intermittent, asymmetrical 
EMG myotonia Yes Yes Yes 
Myopathic EMG Yes No No 
Ring fibres, sarcoplasmic Increase in central nuclei, bland No No 
masses, type I atrophy myopathy, pyknotic nuclear clumps 
Heart block Yes No No 
Liver gamma-GT Yes Yes No 
elevation 
Intellectual impairment ? No No 
Hypersomnia Yes No No 
Table 3b. Clinical and genetic heterogeneity in DM 
Features unlike Atypical DM without PROMM Our family 
DM CTG expansion 
Proximal limb weakness Yes Yes Yes 
Calf hypertrophy Yes Yes Yes 
Trinucleotide r peat No No No 
Linkage to CICNI* Not tested Not present Not tested 
DMI** Not tested Not present Not present 
SCN4A*** Not tested Not present Not present 
* Gene locus on chromosome 7q for muscle chloride channel disorders. 
** Gene locus on chromosome 19q for myotonic dystrophy. 
*** Gene locus on chromosome 17q for muscle sodium channel disorders. 
history to indicate anticipation. Similar to the 
patients described by Thornton et al. [4], there 
are reports of a new dominant disorder with 
intermittent, asymmetrical myotonia, muscle 
weakness and cataracts (proximal myotonic 
myopathy, PROMM) which can masquerade 
as a mild DM variant or as a peculiar form of 
myotonia congenita [16]. Again in these 
patients there was no abnormal CTG expan- 
sion of the DM gene. In this report we describe 
patients from one family showing a clear auto- 
somal dominant inheritance, proximal weak- 
ness, hypogonadism, cataracts, and no 
anticipation. However there were no cardiac 
conduction abnormalities. No elevation of 
serum gamma-GT was found in our patients 
whereas this was a finding in 14 out of 18 
patients described by Ricker et al. [16]. There 
was moderate hypertrophy of calf muscles in 
two of our four patients examined in accor- 
dance with the four patients described in other 
PROMM patients [16]. 
In two out of the four patients examined 
there was mild to moderate atrophy of proxi- 
mal muscles. The mild to moderate proximal 
weakness that we have observed was not 
accompanied by significant muscle wasting or 
severe structural muscle damage. Patients had 
normal deep tendon reflexes and intermittent 
temperature-related myotonia. There was no 
cardiac involvement even at an anatomical level 
as indicated by magnetic resonance imaging 
[20]. These are features which are more consis- 
tent with the proximal myotonic myopathy 
described by Ricker et al. [16], although they 
described two patients with early onset cardiac 
arrhythmias and one of these patients required 
treatment with permanent pacemaker for heart 
block. Our patients had intermittent myotonia 
which was present in only two out of four 
affected patients examined. None of the 
affected individuals by history complained of 
myotonic symptoms. Myotonia was mild, never 
interfering with everyday activities. A 'warm- 
up' phenomenon was present. 
Muscle biopsies taken from the biceps brachii 
of our four patients revealed a nonspecific mild 
myopathy. There was a mild to moderate 
increase in the number of central nuclei as in 
patient IV-6. There was no fibre type grouping, 
PROMM Syndrome 149 
no selective atrophy of type I or type IIb fibres, 
no ring-binden or sarcoplasmic masses. The 
muscle histopathology was not typical for DM 
[7], myotonia congenita and paramyotonia 
congenita [26, 30-33]. 
As in the cases so far described by other 
authors [4, 7, 14, 16], our patients have several 
features compatible with the clinical phenotype 
of DM and several features of PROMM, 
suggesting clinical and genetic heterogeneity of 
patients classified as having atypical DM 
without CTG repeat enlargement or as having 
PROMM. It is possible that the clinical spec- 
trum of PROMM encompasses the families 
reported by Thornton et al. which were called 
atypical DM without CTG repeat expansion. 
At present these patients and those described 
by Ricker et al. [16] might best be classifed as 
having the PROMM syndrome (Table 3a, b). 
From a clinical point of view, it is important to 
distinguish atypical DM and PROMM patients 
from those with DM. Based on the presently 
reported cases, the long-term prognosis for 
patients with PROMM is more favourable than 
for DM. Respiratory failure, mental disturbances 
and a severe congenital form of PROMM have 
not been described. 
The genetic locus responsible for the clinical 
abnormalities in affected individuals in the 
family we have described in this report is 
unknown. The presence of a normal size of the 
CTG repeat in the DM gene and the absence of 
genetic linkage to the loci responsible for 
myotonic dystrophy and sodium channel 
myotonic diseases exclude these genes as candi- 
dates. The study of this family and further 
studies of families with PROMM will increase 
our knowledge of the spectrum of its clinical 
manifestations and will give the opportunity to 
localize and identify the gene locus. Further 
investigations will establish whether the PROMM 
syndrome is a heterogeneous disorder caused 
by more than one gene lesion. 
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